On March 14, 1990, the Centers for Disease Controland the Health Care FinancingAdministrationpublishedcriteria for defining minimum performance in proficiency testing (PT). Using our previously described computer modeling technique, we determined the likelihood of passing PT under the new rules.The model relatescombinationsof intralaboratory CV and bias to PT performance criteria. For example, a laboratory with a bias of zero and an intemal CV of 5% will pass a 10% fixed-limit PT criterion (i.e., the criterion for glucose analyses) 98% of the time when five samples are used. The model providessimilaranalysesfor all PT criteria and all relevantcombinationsof CV and bias.The probability of passing PT decreases as the number of analytes tested increases,i.e., from 98% to 37% as the numberof analytes increases from 1 to 20. A laboratory'sinternal CV has a greatereffect onthe outcomeof PT thandothe corresponding biasvalues. We concludethat a laboratorythat operateswith methods that have internalCVs s33% and biases 20% of the PT criteriawill have a >99% chance of passingPT. 
1, 1991, for current Medicare-certified and CLIAlicensed clinical laboratories (2). Additional regulations required to implement CLIA-1988 amendments, mandating HCFA to promulgate regulations that contain PT for all other laboratories including physician's office laboratories, will follow (3).
The concept of using interlaboratory PT to assess the intralaboratory quality of clinical chemistry tests began with Belk and Sunderman in 1947 (4). Soon thereafter, the College of American Pathologists (CAP) adopted PT as a means of further improving intralaboratory quality. With the enactment of the CUA-1967 regulations, successful participation in an approved PT (such as that of CAP) was federally mandated as a condition of licensure (5). In 1968, Medicare adopted a similar requirement for certification (6). Traditionally, PT 
Materials and Methods
We have demonstrated previously that one can determine the minimum intralaboratory performance levels necessary to meet the requirements specified in the federal rules for PT programs (10, (15) (16) (17) .
Under the plausible and tractable assumption of gaussian imprecision (18), these relationships can be established by computer modeling with a Monte Carlo simulation approach, or by direct calculation based on statistical analysis. In both approaches a laboratory's internal performance characteristics, i.e., its unique imprecision [expressed as the standard deviation (SD) or coefficient of variation (CV)] and its bias, i.e., its offset from the target value, must be taken into account when determining the probability of "passing" one or a series of PT challenges. Other factors such as clerical errors, shipping problems, matrix effects, grading errors, etc., which can amount to 50% of the apparent causes of PT failures, should not be neglected, but a laboratory's analytical prowess is fundamental (19). We computed the relationship between a laboratory's internal CV and (or) bias for a given analyte and the recently published federal interlaboratory PT criteria. Each analyte has its own PT criterion; for the routine chemistry subspecialty, the criteria are identified in Table  1 . By standardizing bias and SD as a percentage of th criteria, in effect obtaining "Z scores," we reduce eac analyte to one generic case for analysis. From given (stan dardized) CV and bias values, we induce a probability o producing a laboratory result outside the (standardized) criterion.
This allows us to determine the probability o passing one PT event under the new format of five sampi per shipment, modeled as a Bernoulli trial.
Required PT Performance
Single analyte. The new regulations specify that "passin performance" Alternatively, the target value can be the mean of resul from 80% of 10 or more referee laboratories (2). From Tabl 1, when "grading" PT results, the acceptable range fo glucose is the target value ± the performance criterion ( performance would be between 900 and 1100 mg/L (5.00-6.10 mmol/L). lithe target value were 500 mg/L (2.78 nunol/L), the acceptable range would be 440 to 560 mg/L (2.44-3.12 mmol/L).
If a laboratory does not achieve at least 80% acceptable erformance on any given analyte (four of five correct esulta) for a PT shipment, the laboratory is, in effect, put n probation for the entire subspecialty in which that articular analyte is listed. To actually "fail" PT and be ubject to "adverse action" (the terms used in the regulaions), the laboratory must again fail to achieve acceptable erformance for the same analyte on one of the next two PT hipments.
Hence, by failing to achieve acceptable perforiance for the same analyte for any two of three consecutive vents, the laboratory may fail the entire subspecialty and iereby suspend testing in the subspecialty. A curious nomaly is that a laboratory could "fail" different analytes, .g., glucose for one PT shipment, uric acid for the next, and K for the third, etc., indefinitely without being suspended i the subspecialty of routine chemistry. Multiple analytes. In addition to passing criteria for the idividual analytes, the regulations require a laboratory to thieve an 80% correct response rate over all analytes in a rticu1ar subspecialty.
To be subject to adverse action, a boratory must have <80% of all results correct for any ro of three consecutive PT shipments.
Obviously, to fail this, a laboratory must also fail at least one analyte, i.e., have two or more incorrect out of five results.
Results and Discussion

Required IntralaboratoryPerformance
One analyte, zero bias. Figure 1 shows the probability of failure, i.e., <80% correct for a laboratory analyzing only one analyte in any one PT shipment. The x-axis is in units of internal CV, or SD as a percent of the PT limit. For example, if the PT limit is 10%, as for glucose (Table 1) , 100 on the x-axis denotes a laboratory with an internal CV of 10%. Under these circumstances, this laboratory has a 51% probability (y-axis) of "failing" the analyte glucose in any one PT shipment, for which it analyzes five PT samples. Figure 1 is based on the assumption that the laboratory has zero bias, i.e., any deviation from the target value is caused only by the laboratory's internal imprecision. Similarly, for analytes whose performance criteria (Table 1 ) are defined as multiples of the group SD, e.g., 3 group SD for alkaline phosphatase, the 100% point on the graph is equivalent to a laboratory whose internal SD is equal to the entire performance criteria, or 3 group SD. Further, if the laboratory's internal CV is 50% of the stated performance limit, the probability of "failing" a single five-sample PT shipment for one analyte drops to just <2%. With an internal CV of 33%, or 1/3 of the PT limit, the laboratory will, in essence, always pass PT. The presence of co-existing bias reduces the "tolerable" CV, as will be shown in subsequent Figures.
Multiple analytes, zero bias. Figure 2 shows the effect of analyzing multiple analytes (glucose, blood urea nitrogen, cholesterol, etc.) on the laboratory's ability to pass PT. In general terms, for any given internal CV, the more analytes tested, the greater the probability that a laboratory will fail one or more analytes. For example, if a laboratory tests two analytes, with each internal CV equal to 100% of the PT performance criteria, the chance of failing at least one analyte increases from 51% to 76%. A laboratory doing 20 analytes, e.g., operating a large, multichannel instrument (acatm, Hitachiw, SMAC, etc.) with all the analytes' CVs equal to 100% of the PT performance criteria, would virtually be assured of failing at least one analyte on every PT event. By reducing the internal CVs to 50% for all analytes, the probability of a failure for the same laboratory doing 20 tests is reduced to 32%. With all CVs below the 33% level, the chances of failure are nearly zero. Obviously, a laboratory's CVs are not consistent across all analytes; some may be considerably <33%, and these tests would cause no problems in PT. However, even two analytes near 50% of the PT criteria would cause a 4% probability of a failure, and two analytes at the 100% level would portend a 76% chance of a failure. Obviously a laboratory should strive to reduce the internal CVs of all its tests to <33% of the performance criteria in Table 1 , but, in particular, should concentrate on reducing the imprecision of any tests with intralaboratory CVs approaching 100% of the PT criteria.
Single and multiple analytes, nonzero bias. Figure 3 shows the likelihood of a laboratory failing a single PT event with co-existing bias (20% and 50% of the PT criterion). As in Figure 2 , the family of curves represents, respectively (from the right to left), the probabilities of failure for one, two, five, 10, 20, and 27 analytes.
The presence of bias increases the likelihood that a laboratory will fail a PT event. In the case of glucose, where the PT criterion is ± 10%, a 20% bias is equivalent to a consistent 20 mg/L (0.11 mmol/L) error. Figures 2 and 3 show the effect of increasing bias on the likelihood of failing a PT event. For one analyte, with biases of 0%, 20%, and 50% of the PT criterion and a consistent co-existing internal CV of 50%, the probability of failure increases from 2% to 4% to 18%, respectively. Further, for 20 analytes, the probability of a failure for biases of 0%, 20%, and 50% increases from 32% to 51% to >98%, respectively. Although a laboratory does not have the same, or for that matter any, bias on every test, any significant bias seriously impairs a laboratory's ability to pass that analyte in a PT shipment. Large bias rather than large imprecision is a common reason for analytical failures (18). Bias from a pipetting error or a reconstitution problem may extend to all analytes and thereby impose a large chance of an 80% failure. Consequently, to pass PT, a laboratory should first minimize the amount of bias for each analyte and then reduce the internal CV, if possible. Figure 4 shows the percent probability of failing a PT event for one analyte as a function of both internal CV and bias. The x-andy-axes depict intralaboratory CV and bias, respectively, as a percentage of the PT limit. The curves have a negative slope, because the presence of bias reduces the "tolerable" internal CV consistent with a given percent probability of a laboratory failing a PT event. The "1" denotes a 1% probability of failing one PT event. As indicated by the continuous line, all combinations of CV and bias falling on the line will yield a 1% chance of failure.
Predicted Failure Rates as a Function of CV and Bias Combinations
Those below (to the left of the line) have less chance of failure. Likewise, curves to the right denote the probabilities of failure of 3%, 5%, etc., for increasing values of CV and bias. Typically, in laboratories in which calibration is performed with reasonable care, biases are small; in laboratories in which biases are >20% and CVs >30% of the performancelimit, both need to be reduced. Ainimizing the Contribution of Bias to the Probabilityof PT :ajlure Figure 5 shows the probability of failing a PT event for ne analyte in a laboratory with various internal CVs and LIIpossible bias values. Bias does not affect the likelihood f failure to the same extent as do CVs of equivalent size. ?or example, if a laboratory reduces its CV to 33% of the ralue in Table 1 for any analyte, a co-existing bias of <40% s tolerable. If the bias can be reduced to <20%, its ontribution to the probability of failure to pass PT is ulmost negligible.
Most authors do not deal with the oncepts of co-existing bias and imprecision, but rather set ias equal to zero (20). Based on Figure 5 , this is a ustiflable assumption, at least when dealing with PT data. ii fact, the traditional function of PT programs has been to educe bias because, even with five samples, PT is ineffec-;ive in measuring intralaboratory imprecision (13).
A laboratory can readily predict the probability of passng PT based on its internal imprecision (CV) and bias. For he proposed two-of-five (or 80%) PT rules, a laboratory v'ith small (<20%) bias can reasonably ensure its likeliiood of passing PT by reducing the imprecision of each inalyte to one-third of the federally mandated performance imit. Thus, particularly for multiple analytes, a laboratory an effect a strategy for passing PT. A laboratory should reduce bias to a minimum by careful nstrument calibration and sample reconstitution and pi-'etting. Once bias is minimized, the laboratory should then oncentrate, in order of priority, on those analytes with the argest CVs by the CDCIHCFA PT criteria. The impreciion of a method is a measurement of the random error. iistorically, laboratories have had little control over relucing random error (21). Consequently, the imprecision of method should be taken into account during method election and evaluation.
Any method that has large ranlom error (internal CV 50% of the PT criteria) should not e considered.
Shrewd laboratory managers, who must asa PT challenges to stay in the "laboratory business," gically should select new instruments and methods in erms of the PT criteria.
As implied in Figure 2 , a laboratory who has successfully pplied the rule of "one-third" to 19 of 20 analytes would, r those 19 analytes, be successful in terms of PT; the 20th ialyte, as depicted for the right-most curve, would determe the probability of the laboratory failing PT, little influenced by the excellent performance on the other analytes. Obviously, a laboratory in which imprecision is marginal for several analytes compounds its probability of failure. Only two analytes, each with CVs of 60% of the PT criteria, increase the probability of failure from 8% to 14% for zero bias and from 10% to 19% with 20% bias.
The new CDCIHCFA rules also incorporate an 80% across-analyte rule, which means that a laboratory must have at least 80% of all PT results correct in a subspecialty. Obviously, a laboratory cannot fail this 80% rule without first having two or more incorrect results for at least one analyte. This rule will not affect laboratories with relatively small (less than one-third of the PT criterion) internal CVs and biases. Instead, problems with PT will arise from the existence of "statistically" introduced failures in individual analytes. For most laboratories, the probability of an 80% failure (across analytes) occurring on two of three consecutive PT shipments is entirely negligible because of the relatively large number of analytes that would score five of five results correctly. For the marginal laboratory, i.e., one in which several analytes have CVs in the 50-100% category, single-analyte failures will be common and the probability of 80% across-analyte failures will gradually increase.
Ed. note: The choice of molar or other units for criteria was made by the regulators, not this Journal. 
